An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Timothy P. Sheahan(University of North Carolina at Chapel Hill), Amy Sims(University of North Carolina at Chapel Hill), Shuntai Zhou(University of North Carolina at Chapel Hill), Rachel L. Graham(University of North Carolina at Chapel Hill), Andrea J. Pruijssers(Vanderbilt University Medical Center), Maria L. Agostini(Vanderbilt University Medical Center), Sarah R. Leist(University of North Carolina at Chapel Hill), Alexandra Schäfer(University of North Carolina at Chapel Hill), Kenneth H. Dinnon(University of North Carolina at Chapel Hill), Laura J. Stevens(Vanderbilt University Medical Center), James D. Chappell(Vanderbilt University Medical Center), Xiaotao Lu(Vanderbilt University Medical Center), Tia M. Hughes(Vanderbilt University Medical Center), Amelia S. George(Vanderbilt University Medical Center), Collin S Hill(University of North Carolina at Chapel Hill), Stephanie A. Montgomery(University of North Carolina at Chapel Hill), Ariane J. Brown(University of North Carolina at Chapel Hill), Gregory R. Bluemling(Emory University), Michael G. Natchus(Emory University), Manohar Saindane(Emory University), Alexander A. Kolykhalov(Emory University), George R. Painter(Emory University), Jennifer L. Harcourt(Centers for Disease Control and Prevention), Azaibi Tamin(Centers for Disease Control and Prevention), Natalie J. Thornburg(Centers for Disease Control and Prevention), Ronald Swanstrom(University of North Carolina at Chapel Hill), Mark R. Denison(Vanderbilt University Medical Center), Ralph S. Baric(University of North Carolina at Chapel Hill)
Cited by 1,160Open Access
Abstract
A ribonucleoside analog inhibits SARS-CoV-2 in human airway epithelial cell cultures and SARS-CoV and MERS-CoV in mice.
Related Papers
No related papers found
Powered by citation graph analysis